Blog

Buying antibiotics now means buying into a stewardship position, whether you intended to or not. Three things about a supplier decide whether your order helps or hurts the resistance picture in your market: which WHO aware group the range sits in, whether every pack can be traced back to a batch and an investigation, and whether the pack size matches the treatment course your prescribers actually use. None of those is a price question, and all three are answerable before you place an order.

The resistance data has moved, and it has moved against import markets

WHO’s global antibiotic resistance surveillance report, published in October 2025, found that one in six laboratory-confirmed bacterial infections worldwide was resistant to antibiotic treatment in 2023. Resistance rose in more than 40 per cent of the pathogen–antibiotic combinations monitored between 2018 and 2023, at an average of 5 to 15 per cent a year.

The regional split is the part that matters to a procurement officer in South Asia or West Africa. In the South-East Asia and Eastern Mediterranean regions, one in three infections was resistant. In the African region, one in five. More than 40 per cent of E. coli and over 55 per cent of K. pneumoniae globally are now resistant to third-generation cephalosporins, and in the African region that figure exceeds 70 per cent. Carbapenem resistance, WHO notes, was once rare and is becoming more frequent.

The mortality forecast points the same way. The Global Research on Antimicrobial Resistance study published in The Lancet in 2024 estimated 1.14 million deaths directly attributable to bacterial AMR in 2021 and 4.71 million associated with it, rising to a projected 1.91 million attributable deaths a year by 2050. Cumulatively, the study forecasts 39 million deaths directly due to AMR between 2025 and 2050, of which 11.8 million are forecast in South Asia — the highest regional burden.

WHO also reported that 48 per cent of countries did not submit surveillance data in 2023. If your national data is thin, your tender specification is doing more work than you think it is.

AWaRe is a procurement category now, not only a clinical one

The WHO AWaRe classification sorts antibiotics into Access, Watch and Reserve groups. At the 2024 UN General Assembly high-level meeting on antimicrobial resistance, member states endorsed a target that by 2030 at least 70 per cent of global human antibiotic consumption should be Access group antibiotics. Progress is tracked annually through GLASS.

That target is a purchasing instruction as much as a prescribing one. A supplier’s range can be mapped to AWaRe in an afternoon, and the map tells you something useful: a portfolio weighted towards Watch and Reserve molecules is a portfolio that will push your national Access share in the wrong direction, regardless of how the products are prescribed. Ask for the range with the AWaRe group written against each molecule. A manufacturer who has never been asked will take a few days; one who cannot produce it at all is worth noting.

Traceability: what “batch traceable” should actually mean

India’s requirement here is narrower than most buyers assume. Under G.S.R. 823(E), notified 17 November 2022 and effective 1 August 2023, drug formulations in the top-300-brand schedule must carry a barcode or QR code encoding a unique product identification code, brand and generic name, manufacturer name and address, batch number, date of manufacture, expiry date and manufacturing licence number — printed on the primary label, or on secondary packaging where there is no room.

That rule does not cover every product, and the parallel export requirement has gone. In February 2025 the Directorate General of Foreign Trade withdrew para 2.76 of the Handbook of Procedures — the long-deferred track-and-trace system for pharmaceutical exports, including primary-level barcoding and parent-child data upload — on the basis that the health ministry’s own barcoding rules and destination-market serialisation requirements now cover the ground.

The practical consequence for an importer: do not assume an Indian-made antibiotic pack carries a serialised code. Ask what is actually printed, at which packaging level, and what the manufacturer can retrieve from a batch number alone — batch record, analytical results, deviation history, distribution list. Traceability that stops at the shipper is not traceability.

Labelling can support stewardship or quietly undermine it

India’s Schedule H1, notified as G.S.R. 588(E) on 30 August 2013 and in force from 1 March 2014, covers certain third- and fourth-generation antibiotics, anti-TB drugs and habit-forming medicines. It requires a red “Rx” symbol and a boxed warning with a red border reading, in part: “It is dangerous to take this preparation except in accordance with the medical advice. Not to be sold by retail without the prescription of a Registered Medical Practitioner.” Retailers must keep a separate register of each supply for three years.

Its measured effect is instructive. A published interrupted time series analysis of Indian sales data from 2008 to 2018 found an immediate 10 per cent reduction in the use of Schedule H1 medicines after implementation and a sustained 9 per cent trend decline — while overall antimicrobial consumption kept rising, and carbapenem use went up. Labelling changes behaviour at the margin. It does not carry a stewardship programme on its own.

Product selection matters more than label text. In August 2024 India’s health ministry prohibited 156 fixed-dose combinations, including antibiotic combinations, on the Drugs Technical Advisory Board’s advice, as irrational combinations carrying risk where safer alternatives exist. If a quotation offers you an antibiotic FDC, the first question is whether it is approved in India and in your own market — not what it costs.

Pack design is a stewardship decision

Pack size sets treatment duration in practice, because patients are told to finish the pack. A 2015 Australian analysis of common primary-care prescribing scenarios found that of 32 scenarios, ten pack sizes supplied surplus doses, eighteen supplied too few, and only four matched the guideline course. Surplus antibiotics end up in a cupboard, taken later by the patient or by somebody else, or discarded into waste water where they contribute to resistant strains.

This is one of the few stewardship levers a buyer controls directly. Specify the course, not the count, and ask the manufacturer to build the blister to it.

Six questions worth putting to an antibiotic manufacturer

Ask	A good answer looks like	Why it matters
Map your antibiotic range to WHO AWaRe groups	A product list with Access / Watch / Reserve marked against each molecule	Tells you whether the order moves your national Access share towards or away from the 70% target
What is printed on the pack, and at which packaging level	Specific: fields encoded, primary or secondary label, whether codes are serialised	India’s barcode rule does not cover every product, and the DGFT export track-and-trace requirement was withdrawn in 2025
What can you retrieve from a batch number alone	Batch record, analytical results, deviations, distribution list — with a stated turnaround	This is what a recall or a field complaint actually runs on
Which blister configurations can you build to a treatment course	Willingness to quote more than one configuration and a stated minimum batch size	Pack size sets duration in practice; mismatched packs create leftover antibiotics
Stability data at 30°C/75% RH for the exact pack offered	Pack-specific data, not product-general data	Barrier properties differ by pack; the destination climate does not care what the product can do in another one
Any Not of Standard Quality declaration on these products, and what changed	A direct answer, the investigation conclusion, and the corrective action	Substandard antimicrobials feed resistance directly; a supplier who deflects here will deflect later

How Salus approaches this

Salus Pharmaceuticals manufactures at a WHO-GMP and ISO 9001:2015 certified facility in Baddi, Himachal Pradesh, operating since 2005 across 21-plus therapeutic categories, with tablets and capsules  supplied in blister packs and  in alu-alu. Antibiotic enquiries are answered with the molecule, strength, pack configuration and pack-specific stability position together, because those four determine whether an order is usable in the destination market.

[Download the antibiotic range sheet →]

https://www.saluspharmaceuticals.com/products.html#antibiotics

Baddi is a formulation cluster because of a tax decision, not a geographical or technical one. In 2003 the central government gave new industrial units in Himachal Pradesh a ten-year exemption from central excise duty and a five-year income tax holiday, and manufacturers moved up from Punjab and Haryana to claim it. Those incentives have almost entirely run out. What is left is a dense supply base, a large number of plants of very uneven quality, and a buyer’s problem: the postcode no longer tells you anything.

What the 2003 package actually gave

The special industrial package covered Himachal Pradesh alongside Uttarakhand, Jammu and Kashmir and the North East. For a new unit it meant ten years free of central excise duty and five years free of income tax, on top of state-level subsidies and cheaper power.

The excise clock ran from each unit’s own start of commercial production rather than from a common date, which is why the belt did not lose the benefit all at once. Reporting from 2013 put roughly 250 pharma SMEs in the Baddi–Barotiwala–Nalagarh region — 75 to 80 per cent of the pharma units there — facing expiry between 2014 and 2016. The income tax holiday was curtailed earlier, in 2010.

The predicted consequence arrived. Contract manufacturers without their own marketed products, which had been built on a cost advantage rather than a customer base, went looking for buyers or joint ventures. Over-capacity and thin margins became the region’s normal condition, and they still are.

What replaced the exemption

When GST came in on 1 July 2017 the exemption mechanism itself disappeared. The Scheme of Budgetary Support, notified on 5 October 2017, reimburses eligible units 58 per cent of the central tax and 29 per cent of the integrated tax paid in cash, for what the scheme calls the “residual period” — the remainder of the original ten years from the unit’s start of commercial production.

The date to note is in the scheme itself: “The overall scheme shall be valid upto 30.06.2027.” After that there is no tax reason to make tablets in Baddi rather than anywhere else in India. Any plant that still depends on the residual subsidy for its cost position has a little under a year of it left.

Baddi’s origin story, in dates

When	What changed
2003	Central industrial package: ten-year central excise exemption and five-year income tax holiday for new units in Himachal Pradesh
2010	Income tax holiday curtailed; units established by then retained benefits into the following decade
2014–2016	Excise exemption expires unit by unit for the bulk of BBN’s pharma SMEs; consolidation and distress sales follow
1 July 2017	GST replaces central excise; the exemption route ends
5 Oct 2017	Scheme of Budgetary Support notified — 58% of CGST and 29% of IGST reimbursed for the residual period only
28 June 2024	Revised Schedule M becomes applicable to manufacturers above Rs 250 crore turnover
11 Feb 2025	G.S.R. 127(E) gives smaller manufacturers who applied in time until 31 December 2025 to comply
31 Dec 2025	That extension expires
30 June 2027	Scheme of Budgetary Support ends

What actually remains

The cluster effect. The Tribune reported in 2025 that the belt holds more than 350 manufacturing units, of which around 150 carry FDA approvals, and that Himachal Pradesh exported pharmaceutical products worth about Rs 10,000 crore in 2023.

For a buyer, density is the real asset. Blister foil, alu-alu foil, cartons, printed inserts, shippers, engineering spares, qualified maintenance contractors and analytical laboratories are all within an hour’s drive. A packing change that would take a fortnight to source elsewhere takes days. Recruitment of production and QA staff draws on a pool that has worked in the same industry in the same valley. None of this is a quality claim. It is a lead-time and cost-of-change claim, and it is the one that survives the end of the tax holiday.

The uncomfortable part

Concentration cuts both ways, and the enforcement record is public. In the November 2025 monthly drug alert, 49 of 205 samples declared Not of Standard Quality nationally — 23.09 per cent — were traced to units in Himachal Pradesh, across Baddi, Barotiwala, Nalagarh, Solan, Kala Amb, Paonta Sahib and Una. The state drugs controller issued show-cause notices, ordered batch recalls and began risk-based inspections of the deficient units.

That is a state-level statistic, not a verdict on any individual plant, and it is exactly why a buyer should stop treating “Baddi” as a credential. Nationally, CDSCO and state drug controllers inspected 400 premises on a risk basis and took more than 300 actions — show-cause notices, stop-production orders, licence suspensions and cancellations. India is also not a member of the Pharmaceutical Inspection Co-operation Scheme, and CDSCO does not appear on the PIC/S list of applicants as of September 2026, so there is no mutual-recognition shortcut that lets you skip your own assessment.

What to judge a Baddi plant on

Ask about the plant, not the region.

Which Schedule M cohort it was in, and what it did. Revised Schedule M applied to manufacturers above Rs 250 crore turnover from June 2024. Smaller manufacturers had to apply for an extension under G.S.R. 127(E) and comply by 31 December 2025. Ask which category the plant fell into, whether it applied, and what was physically upgraded — not whether it “complies”.

The certificate scope, not the certificate. A WHO-GMP certificate covers specified sections of a site. Confirm that the section making your dosage form is named on it, and ask for the date of the last joint inspection.

Its own quality record, in writing. Ask directly whether any of the plant’s products have been declared Not of Standard Quality, what the investigation concluded and what changed. A manufacturer that cannot discuss this calmly is telling you something.

Whether it makes for itself or for others. A pure contract manufacturer, a brand owner and an exporter have different incentives around batch size, changeover and documentation. None is wrong; they are not interchangeable.

Stability data for your climatic zone and your pack. Baddi’s own climate is irrelevant to a shipment landing in Lagos or Chattogram. Ask for 30°C/75% RH data on the exact pack.

How Salus approaches this

Salus Pharmaceuticals has manufactured formulations in Baddi since 2005 at a WHO-GMP and ISO 9001:2015 certified facility, with over 200 staff, 21-plus therapeutic categories, and tablets, capsules and oncology formulations packed in blister, alu-alu and aluminium formats. Buyers assessing the plant are shown the site, the certificate scope and the documentation system rather than a presentation about the region.

A Certificate of Pharmaceutical Product proves three administrative facts and nothing more: that one specific product holds a marketing authorisation in the exporting country, whether that product is actually sold there, and that the site making it has been inspected against WHO GMP. It says nothing about the batch in your container. If you are registering an Indian product for the first time, understanding that boundary will save you a rejection and a wasted authentication cycle at your embassy.

One product, one certificate

The WHO guidance is explicit that the certificate “is for a single product only since the manufacturing arrangements and approved information for different dosage forms and different strengths can vary.” A 500 mg tablet and a 250 mg tablet of the same molecule are two certificates. A twelve-product order is twelve certificates.

This is where most first enquiries go wrong. Buyers ask a manufacturer to “send your COPP”, expecting a single document covering the factory. That document exists, but it is a different one — the WHO-GMP certificate, which covers the site and the categories of product licensed there. The CoPP is the product-level certificate built on top of it. Ask for both, and ask for the CoPP product by product against the exact strengths and pack presentations you intend to register.

The three lines an overseas regulator reads first

The WHO model certificate runs to several numbered boxes, but a reviewing assessor goes straight to three of them.

Box 1.3 asks: “Is this product authorized by the certifying authority to be marketed in the certifying country or within the jurisdiction of the certifying regional authority?” A “No” here is not automatically fatal, but it moves the file into a different queue.

Box 1.4 asks: “Is this product actually on the market in the certifying country?” — with Yes, No or Unknown as the permitted answers. This is the box that surprises importers. Plenty of Indian-made products are manufactured for export only. Under the CDSCO export No Objection Certificate route, the manufacturer undertakes that “the entire quantity… shall be exported and no part of it will be diverted for domestic sale in India”, and the pack is labelled “For export only – Not for domestic consumption.” That is a lawful, documented arrangement — but it produces a “No” in box 1.4, and some importing authorities treat that answer as a reason to ask for more.

Box 3.5 asks whether “the facilities and operations of the manufacturer of the FPP conform to good manufacturing practices (GMP) as recommended by WHO.” This is the line the certificate exists for. Read it alongside the site’s WHO-GMP certificate and the date of the last inspection.

Who issues it, and how long the process takes

CDSCO administers the WHO certification scheme in India in coordination with the State Licensing Authorities. For a plant in Himachal Pradesh, the application is made to the State Licensing Authority and the inspection is a joint one, carried out by CDSCO zonal or sub-zonal officers together with state representatives.

How long it stays valid — two answers, not one

The WHO guidance leaves validity to the issuing authority: “A period of validity can be provided by the authority on the certificate.” There is no universal expiry.

In Indian practice, WHO-GMP certificates and CoPP have carried a three-year validity since 2018, when the Drugs Controller General extended it from two years. That figure has moved before — in May 2020 CDSCO extended certificates expiring between March and August 2020 by a further six months — so verify the dates printed on the actual document rather than assuming the rule.

The validity that constrains you, though, is usually the importing regulator’s. NAFDAC, for example, requires that the certificate be issued by the health or regulatory body in the country of manufacture, conform to WHO format, and be authenticated by the Nigerian Embassy or High Commission in the country of origin — with a Commonwealth or ECOWAS mission acceptable where no Nigerian mission exists. The accompanying cGMP certificate must be “valid at the time of submission.” Authentication takes weeks. A certificate with eight months left on it can still be too old by the time your dossier is assessed.

What a CoPP does not prove

It does not certify the consignment. WHO deals with individual consignments through a separate instrument — the batch certificate, which “refers to an individual batch” and is described as a vital instrument in the procurement of medicines. The CoPP is for registration; the batch certificate and certificate of analysis are for the shipment. Treating a CoPP as a quality release is a category error, and it is the one that most often shows up in a first-time importer’s file.

It also does not attest bioequivalence, stability in your climatic zone, or suitability of the pack for your market. Box 4 asks only whether “the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product” — a statement about that authority’s satisfaction, not a technical opinion you can use in place of data.

Reading a WHO-format CoPP: the boxes that matter

Box	What it asks	What to do with the answer
1.3	Is the product authorised to be marketed in the certifying country?	If “No”, go straight to box 2.B for the reason before anything else
1.4	Is the product actually on the market there? (Yes / No / Unknown)	“No” is normal for export-only products — ask for the export NOC and a specimen of the “For export only” label
2.A.1	Marketing authorisation number and date of issue	Check it matches the exact strength and dosage form you are registering, not a sister product
2.B	If not authorised, the reason: not required / not requested / under consideration / refused / withdrawal for commercial reasons / withdrawal for sanitary reasons	“Refused” or “withdrawal for sanitary reasons” ends the assessment. The others do not
3.5	Do the facilities conform to WHO-recommended GMP?	Pair with the site WHO-GMP certificate and the date of the last inspection
4	Does the applicant’s submitted information satisfy the certifying authority?	A “No” here is rare and material — ask what was outstanding

How Salus approaches this

Salus Pharmaceuticals manufactures at a WHO-GMP and ISO 9001:2015 certified facility in Baddi, Himachal Pradesh, and has done so since 2005. Certification documents are issued product by product through the State Licensing Authority route described above, and export documentation for Nigeria, Bangladesh and Sri Lanka is prepared against each destination regulator’s own authentication and currency requirements rather than as a single standard pack.

Need COPP documentation for your products?

[Ask for our current CoPP list, product by product →]

https://www.saluspharmaceuticals.com/contact.html

Antidiabetic Tablets Manufacturer India | Salus Pharmaceuticals

Three things decide whether a diabetes order works commercially in an emerging market, and none of them is the molecule. Metformin still anchors almost every treatment plan. Price is set by public procurement rather than by the pharmacy shelf. And pack size moves the landed cost more than the active ingredient does. Buyers who understand those three points stop guessing at diabetes tenders and start costing them.

The demand is concentrated where budgets are thinnest

The International Diabetes Federation now puts the number of adults aged 20–79 living with diabetes at 589 million, or 11.1% of that age group, rising to a projected 853 million by 2050. That is 45% growth against roughly 25% population growth over the same period — diabetes is outrunning demography.

The number that matters more to a procurement officer is the undiagnosed one. Around 252 million adults — 42.8% of everyone with diabetes — do not yet know they have it, and 86.9% of those undiagnosed cases sit in low- and middle-income countries. In South-East Asia, 42.7% of the diabetic population is undiagnosed.

That gap is the forecasting problem. Africa currently records the world’s lowest age-standardised prevalence at 5.0%, but it is not a low-demand market — it is a low-diagnosis market. Every screening programme, every insurance expansion, every new district-level clinic converts undiagnosed prevalence into prescriptions, and the demand curve steps up rather than sloping. If you forecast a diabetes tender on today’s dispensing volumes alone, you will under-order. Forecast on diagnosis capacity instead.

Metformin still anchors the order book

The therapeutic conversation has moved on considerably. In September 2025 the WHO added semaglutide, dulaglutide, liraglutide and tirzepatide to its Model List of Essential Medicines — but for a deliberately narrow group: adults with type 2 diabetes who also have established cardiovascular disease or chronic kidney disease and obesity. In the same announcement, the WHO was blunt that “high prices of medicines like semaglutide and tirzepatide are limiting access,” and called for generic competition to bring them down .

Affordability pressure is structural, not seasonal

In India, scheduled antidiabetic formulations sit under ceiling prices set by the NPPA under the Drug Prices Control Order. Published research on partial price control of metformin has shown a predictable consequence: when only some strengths and forms are controlled, the market shifts toward combinations and presentations that are not. Any manufacturer quoting an Indian-market diabetes product is quoting inside that structure, and any importer benchmarking against Indian domestic prices should know which side of the schedule they are looking at.

Export and institutional tenders apply the same pressure by a different route: lowest-evaluated-bid award. On a molecule as commoditised as metformin, no amount of formulation cleverness recovers a bad price. The margin is not in the API. It is in batch size, packing efficiency, yield, and rejection rate — the four things a buyer can actually influence by how they write the enquiry.

Pack size decides the tender price

This is the point most enquiries miss. On a low-cost, high-volume tablet, primary packing, carton, insert and shipper can account for a substantial share of ex-works cost. Change the pack configuration and you change the bid.

The shape of the effect, using illustrative figures — plug in current rates before you rely on them:

Pack configuration	Packing cost per tablet	Notes
10s blister	Highest	Familiar retail pack; most foil and carton per tablet
15s alu -alu	High	Common private-channel size in South Asia.  Better moisture barrier, fewer cartons per thousand tablets
100s HDPE container	Lowest	Cheapest per tablet; needs dispensing infrastructure at the clinic.  Strong fit for institutional dispensing

Two cautions before you optimise straight to the largest pack. First, metformin tablets are physically large, especially at higher strengths, so pack volume drives freight and warehouse cost as well as material cost — a container’s worth of 10s blisters holds far fewer treatment courses than the same container of bulk packs. Second, the pack has to survive the market it ships to: stability at 30°C/75% relative humidity has to be demonstrated for the specific pack you intend to buy, not for the product in general.

The practical fix is simple. Ask for two or three pack configurations in every quotation, not one.

Four questions worth putting in the enquiry

1. Which strengths, and immediate- or sustained-release? These are different manufacturing routes with different costs — settle it before pricing.
2. Stability data at 30°C/75% RH for the exact pack offered. A quote without pack-specific stability data is not yet a quote.
3. Blister, alu-alu or HDPE — with a packing cost per tablet for each. This is where the bid is won.
4. Batch size and minimum order at each configuration. A price that only holds at a batch size you will never order is not a usable price.

How Salus approaches diabetic care

Salus Pharmaceuticals has manufactured formulations at its WHO-GMP and ISO 9001:2015 certified facility in Baddi, Himachal Pradesh since 2005, with diabetic care among its 21-plus therapeutic categories. Tablets are supplied in blister and capsules in alu-alu packs, and diabetes enquiries are quoted across more than one pack configuration as a matter of course, because the configuration is usually what decides whether the order is viable.

Send us the strengths, the annual volume and the destination market, and we will come back with a costing across pack options rather than a single line item.

[View the diabetic care range →]

Zero-defect manufacturing isn’t a claim we make — it’s a system we built.

In oncology, there is no margin for a mix-up. A wrong carton, a delayed invoice reconciliation, an unqualified operator running a compression machine, an audit finding that surfaces six months too late — any one of these can cost a brand its regulatory standing, its market, or worse, patient trust.

At Salus Pharmaceuticals — a WHO-GMP and ISO 9001:2015 certified formulation manufacturer under the Arvincare Group, based in Baddi, Himachal Pradesh — we took a simple position: the way to eliminate risk for our customers is to remove the human error points from every system that touches their product, their money, and their compliance record.

Over the last year, we’ve built and deployed a set of purpose-engineered digital systems across our operations. Here’s what they do, and why they matter to any brand — especially in oncology — considering Salus as a manufacturing partner.

---

1. CDR / Artwork Version Control — Zero Wrong-Print Risk

Printed packaging material is one of the most under-appreciated risk points in contract manufacturing. A vendor working off an old email, printing an outdated carton design, can trigger a recall before a single tablet is even packed.

We built a single source of truth system for every carton, leaflet, cylinder, and printed foil we handle. Only one CDR version is ever “live” per item. Every purchase order for printed material is auto-checked against the master version — if a vendor is quoted or supplied an outdated version, the system flags it automatically before mass printing is ever authorized. No print run proceeds without a system-verified “OK TO PRINT.”

What this means for you: your artwork is protected from the moment it’s approved to the moment it reaches a carton — with a full change log proving exactly when and why each version changed, ready for any auditor who asks.

2. CRM & Collections FMS — Transparent, Verifiable Business Dealings

Every commercial relationship runs on trust in the numbers. Our CRM Collection system tracks every invoice, every receipt, and every ageing bucket — with receipts verified independently by Accounts, never by the person managing the relationship. A 100-point scorecard and automated integrity checks mean nothing slips through informally.

What this means for you: full visibility into your account status at any time, with a system that makes disputes and reconciliation errors structurally rare rather than something you have to chase down.

3. APQR Format Pack & FMS — Audit-Ready Quality Data, Always

Annual Product Quality Reviews are where regulatory relationships are won or lost. Our APQR system runs across 21 standardized formats with built-in Cp/Cpk statistical analysis, a data-provenance log for every figure, and completeness gates that block a review from closing until every data point is verified and sourced.

What this means for you: when your regulatory team — or a WHO inspector, or a third-party auditor — asks “show me the trend data behind this batch,” the answer is one query away, not a week of digging through files.

4. Self Inspection FMS — Continuous Compliance, Not Once-a-Year Panic

Self-inspection under Schedule M and WHO-GMP isn’t a checkbox exercise for us. Our system enforces the independence of every auditor, guarantees full coverage across all areas due for review, and — critically — makes retroactive date changes on any inspection impossible, because entries are locked in through a form-driven, timestamp-verified process the moment they’re submitted.

What this means for you: the audit trail you’re relying on for your own regulatory submissions is real, timestamped, and cannot be quietly edited after the fact.

5. Tablet Production Operator Scoring — Consistent Hands on Every Batch

Batch-to-batch consistency starts with the people running the machines. We track operator qualification, machine-specific competency, and run-level performance across all 13 machines on our compression, coating, and granulation lines — with a scoring model that actively rewards operators for self-reporting errors and penalizes errors only caught later by audit or QA. That single design choice changes behavior: operators tell us the truth early, instead of hiding a deviation and hoping it isn’t found.

What this means for you: the operator standing at the machine producing your batch is qualified for that exact machine, and the incentive structure around them is built to surface problems before they become yours.

---

The Common Thread: Systems That Can’t Be Gamed

Every system above shares the same design DNA:

• No hand-typed dates. Every timestamp comes from a system source — a form submission, a master record — never a manual entry that could be backdated.
• Segregation of duties, enforced by the system itself. The person being evaluated can never be the person who signs off on the evaluation.
• Traceability by default. ALCOA+ principles aren’t a training slide here — they’re built into how data is captured, so every number has a verifiable origin.

This isn’t compliance theater. It’s infrastructure that happens to make audits painless as a byproduct of making the underlying operations genuinely more reliable.

Why This Matters More in Oncology

Oncology formulations carry tighter tolerances, higher scrutiny, and less room for the kind of “we’ll fix it next batch” thinking that other therapeutic categories can sometimes absorb. A partner whose quality systems are built to withstand a WHO inspector’s toughest question — and whose commercial systems are built to withstand your own finance team’s toughest reconciliation — is a partner you can scale with, not just contract with.

What This Means for Your Growth

When your contract manufacturer has removed the error points from packaging, quality documentation, self-inspection, operator performance, and commercial reconciliation, the compounding effect shows up in your business, not just ours:

• Faster regulatory approvals — because your dossiers are backed by audit-ready, provenance-tracked data from day one.
• Fewer recalls and market-risk events — because the packaging error that caused a 50,000-unit misprint elsewhere in the industry is structurally prevented here.
• Predictable, disputable-free commercial dealings — so your finance team spends time growing the relationship, not auditing it.
• A partner that scales with you — because these are systems, not individual heroics, which means the reliability holds as volumes grow.

We keep building. Every one of these systems started because something went wrong once, and we decided the right fix wasn’t “be more careful” — it was “build a system where the error can’t happen quietly again.”

That’s the partnership we’re offering.

---

Salus Pharmaceuticals — WHO-GMP & ISO 9001:2015 certified formulation manufacturer, Arvincare Group, Baddi, Himachal Pradesh.